Clinical Trials on Metastatic Triple-Negative Breast Cancer in China

Total 2081 results

Cancer Institute and Hospital, Chinese Academy...

Recruiting

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer

China
Akeso

Recruiting

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Metastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast Cancer

China
Huihua Xiong

Not yet recruiting

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer

China
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Metastatic Breast Cancer | Metastatic Triple Negative Breast Cancer

Japan, Belgium, France, Netherlands
Sun Yat-sen University

Terminated

Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer (SYSUCC-007)

Metastatic Triple Negative Breast Cancer

China
Gilead Sciences
Parexel; IQVIA RDS (Shanghai) Co., Ltd.; Medidata Solutions; Q Squared Solutions...

Active, not recruiting

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Metastatic Triple-negative Breast Cancer

China
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)

Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast Cancer

Japan
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Metastatic Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer

Metastatic Breast Cancer

China
Fudan University

Unknown

Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer

Metastatic Breast Cancer

China
Fudan University

Active, not recruiting

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (SPARK)

Metastatic Breast Cancer

China
Fudan University

Recruiting

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Guangdong Provincial People's Hospital
First Affiliated Hospital, Sun Yat-Sen University; Henan Cancer Hospital; Dongguan... and other collaborators

Completed

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
Beijing 302 Hospital

Recruiting

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer (TNBC)

China
Peking University

Recruiting

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

HER2-positive Breast Cancer | Triple-negative Breast Cancer

China
Fudan University

Recruiting

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01)

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) (CITRINE)

Triple-negative Breast Cancer

China
Fudan University

Active, not recruiting

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Triple-Negative Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy

Triple-negative Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
Fudan University

Not yet recruiting

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Fudan University

Recruiting

Reverse Triple Negative Immune Resistant Breast Cancer (Renaissance)

Triple-negative Breast Cancer

China
Fudan University

Recruiting

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Taizhou Hanzhong biomedical co. LTD

Active, not recruiting

A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

Triple-negative Breast Cancer

China
Fudan University

Recruiting

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype (BCTOP-T-M03)

Metastatic Breast Cancer | Triple Negative Breast Cancer | Mutation

China
First Affiliated Hospital Bengbu Medical College

Recruiting

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Triple-negative Breast Cancer

China
Sichuan Provincial People's Hospital

Recruiting

A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer (NeoATCT)

Triple-negative Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC (Apollo)

Triple-negative Breast Cancer

China
Guangdong Provincial People's Hospital

Completed

Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (LANCET)

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
First Affiliated Hospital of Shantou University...
Guangdong ProCapZoom Biosciences Co., Ltd.

Not yet recruiting

Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer

Advanced Triple Negative Breast Cancer

China
Fudan University

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer

China
Fudan University

Completed

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Advanced Triple-Negative Breast Cancer

China
Biotheus Inc.

Not yet recruiting

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer(TNBC)

China
Jiangxi Provincial Cancer Hospital

Recruiting

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Triple-Negative Breast Cancer

China
Huihua Xiong

Recruiting

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study (UTILIZABLE)

TNBC - Triple-Negative Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
Aiping Shi

Recruiting

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC)

China
Fujian Cancer Hospital

Not yet recruiting

Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Advanced Triple Negative Breast Cancer

China
Fudan University

Not yet recruiting

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Triple-Negative Breast Cancer

China
First Affiliated Hospital of Zhejiang University
Shanghai Longfine Biotechnology Co., Ltd.; TopAlliance

Not yet recruiting

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Triple-negative Breast Cancer

China
Hebei Medical University Fourth Hospital
Beijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Breast Cancer | Triple-negative Breast Cancer | Nab-paclitaxel

China
Fudan University

Recruiting

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (QUEEN-Dream)

Neoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast Cancer

China

3

Subscribe